Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome.

Journal of medical genetics - 1 Dec 2008

Sagelius H, Rosengardten Y, Schmidt E, Sonnabend C, Rozell B, Eriksson M

Abstract excerpt

Hutchinson-Gilford progeria syndrome (HGPS) is a rare progeroid syndrome caused by mutations in the LMNA gene. Currently there is no treatment available for HGPS, but promising results from several studies using farnesyl transferase inhibitors (FTIs) on cells and animal models of HGPS have been published and a clinical trial using FTIs has been started in patients with HGPS. However, the published data from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to Disease Models, Animal
Share to Epidermis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Lamin Type A

Share to Lamins

Share to Mice, Transgenic

Share to Progeria

Source

Identifiers

PMID: 18708427
DOI: 10.1136/jmg.2008.060772

Genes

LMNA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversible phenotype in a mouse model of Hutchinson-Gilford progeria syndrome.PMID 18708427Read ↗

Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease.Semantic proximity Read ↗

Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.Semantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy TreatmentSemantic proximity Read ↗

Splicing-directed therapy in a new mouse model of human accelerated aging.Semantic proximity Read ↗

Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Generation and characterization of a novel knockin minipig model of Hutchinson-Gilford progeria syndromeSemantic proximity Read ↗

Transient expression of an adenine base editor corrects the Hutchinson-Gilford progeria syndrome mutation and improves the skin phenotype in mice.Semantic proximity Read ↗

NLRP3 inflammasome inhibition rescues Hutchinson-Gilford Progeria cellular phenotype and extend longevity of an animal modelSemantic proximity Read ↗

Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Impaired Lef1 activation accelerates iPSC-derived keratinocytes differentiation in Hutchinson-Gilford Progeria SyndromeSemantic proximity Read ↗

Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.